379 related articles for article (PubMed ID: 27930669)
1. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
2. RT-PCR assay to detect
Priesterbach-Ackley LP; van Kuik J; Tops BBJ; Lasorella A; Iavarone A; van Hecke W; Robe PA; Wesseling P; de Leng WWJ
Neurooncol Pract; 2024 Apr; 11(2):142-149. PubMed ID: 38496910
[TBL] [Abstract][Full Text] [Related]
3. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
4. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
[TBL] [Abstract][Full Text] [Related]
5. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
6. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic FGFR3 gene fusions in bladder cancer.
Williams SV; Hurst CD; Knowles MA
Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
[TBL] [Abstract][Full Text] [Related]
8. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
11. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
12. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
[TBL] [Abstract][Full Text] [Related]
13. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.
Sarkar S; Ryan EL; Royle SJ
Open Biol; 2017 Aug; 7(8):. PubMed ID: 28855393
[TBL] [Abstract][Full Text] [Related]
14. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
15. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
16. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
19. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
Gött H; Uhl E
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
[TBL] [Abstract][Full Text] [Related]
20. A novel somatic FGFR3 mutation in primary lung cancer.
Shinmura K; Kato H; Matsuura S; Inoue Y; Igarashi H; Nagura K; Nakamura S; Maruyama K; Tajima M; Funai K; Ogawa H; Tanahashi M; Niwa H; Sugimura H
Oncol Rep; 2014 Mar; 31(3):1219-24. PubMed ID: 24452392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
